18 June 2014 - Deborah Wilkes
Archived
Canada's Valeant Pharmaceuticals International has taken its unsolicited takeover offer for Allergan directly to shareholders, after the board of the Botox maker rejected the proposal valuing the company at around US$53 billion.
New to OTCToolbox?
This is available as part of an Annual Subscription to the OTCToolbox website.